Stem Cell Clinic

Biobanks Market To Witness An Impressive Growth During The Forecast Period 2017 2025 Dagoretti News – Dagoretti News

By Stell Cell Research

The global Biobanks market study encloses the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). With bottom-up and top-down approaches, the report predicts the viewpoint of various domestic vendors in the whole market and offers the market size of the Biobanks market. The analysts of the report have performed in-depth primary and secondary research to analyze the key players and their market share. Further, different trusted sources were roped in to gather numbers, subdivisions, revenue and shares.

The research study encompasses fundamental points of the global Biobanks market, from future prospects to the competitive scenario, extensively. The DROT and Porters Five Forces analyses provides a deep explanation of the factors affecting the growth of Biobanks market. The Biobanks market has been broken down into various segments, regions, end-uses and players to provide a clear picture of the present market situation to the readers. In addition, the macro- and microeconomic aspects are also included in the research.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321&source=atm

Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

Purchase reports at discounted prices!!! Offer valid till midnight!!!

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=2321&source=atm

The Biobanks market research covers an exhaustive analysis of the following data:

The Biobanks market research addresses critical questions, such as

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=2321&source=atm

The global Biobanks market research considers region 1 (Country 1, country 2), region 2 (Country 1, country 2) and region 3 (Country 1, country 2) as the important segments. All the recent trends, such as changing consumers demand, ecological conservation, and regulatory standards across different regions are covered in the report.

Read the rest here:
Biobanks Market To Witness An Impressive Growth During The Forecast Period 2017 2025 Dagoretti News - Dagoretti News

Stem Cell Alopecia Treatment Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 – Vital News 24

By Stell Cell Research

Stem Cell Alopecia Treatment Market

New Jersey, United States, The report offers an all-inclusive and accurate research study on the Stem Cell Alopecia Treatment Market while chiefly that specialize in current and historical market scenarios. Stakeholders, market players, investors, and other market participants can significantly have the benefit of the thorough marketing research provided within the report. The authors of the report have compiled an in depth study on crucial market dynamics, including growth drivers, restraints, and opportunities. This study will help market participants to induce a decent understanding of future development of the Stem Cell Alopecia Treatment market. The report also focuses on market taxonomy, regional analysis, opportunity assessment, and vendor analysis to assist with comprehensive evaluation of the Stem Cell Alopecia Treatment market.

Request a Sample Copy of this report @https://www.verifiedmarketresearch.com/download-sample/?rid=15102&utm_source=VN24&utm_medium=002

Top 10 Companies in the Global Stem Cell Alopecia Treatment Market Research Report:

Global Stem Cell Alopecia Treatment Market: Competitive Landscape

The research analysts who have authored this report are experts in performing competitive analysis of the global Stem Cell Alopecia Treatment market. They have deeply profiled leading as well as other players of the global Stem Cell Alopecia Treatment market with large emphasis on their market share, recent developments, business overview, markets served, and growth strategies. The report not only provides valuable insights into the competitive landscape but also concentrates on minor as well as major factors influencing the business of players. The product portfolios of all companies profiled in the report are compared in quite some detail in the product analysis section.

Global Stem Cell Alopecia Treatment Market: Segment Analysis

The global Stem Cell Alopecia Treatment market is segmented according to type, application, and region. The analysts have carefully studied each segment and sub-segment to provide a broad segmental analysis of the global Stem Cell Alopecia Treatment market. The segmentation study identifies leading segments and explains key factors supporting their growth in the global Stem Cell Alopecia Treatment market. In the regional analysis section, the report authors have shown how different regions and countries are growing in the global Stem Cell Alopecia Treatment market and have predicted their market sizes for the next few years. The segmental analysis will help companies to focus on high-growth areas of the global Stem Cell Alopecia Treatment market.

Global Stem Cell Alopecia Treatment Market: Regional Analysis

This part of the report includes detailed information of the market in different regions. Each region offers different scope to the market as each region has different government policy and other factors. The regions included in the report are North America, South America, Europe, Asia Pacific, and the Middle East. Information about different region helps the reader to understand global market better.

Ask for Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=15102&utm_source=VN24&utm_medium=002

Table of Content

1 Introduction of Stem Cell Alopecia Treatment Market

1.1 Overview of the Market 1.2 Scope of Report 1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining 3.2 Validation 3.3 Primary Interviews 3.4 List of Data Sources

4 Stem Cell Alopecia Treatment Market Outlook

4.1 Overview 4.2 Market Dynamics 4.2.1 Drivers 4.2.2 Restraints 4.2.3 Opportunities 4.3 Porters Five Force Model 4.4 Value Chain Analysis

5 Stem Cell Alopecia Treatment Market, By Deployment Model

5.1 Overview

6 Stem Cell Alopecia Treatment Market, By Solution

6.1 Overview

7 Stem Cell Alopecia Treatment Market, By Vertical

7.1 Overview

8 Stem Cell Alopecia Treatment Market, By Geography

8.1 Overview 8.2 North America 8.2.1 U.S. 8.2.2 Canada 8.2.3 Mexico 8.3 Europe 8.3.1 Germany 8.3.2 U.K. 8.3.3 France 8.3.4 Rest of Europe 8.4 Asia Pacific 8.4.1 China 8.4.2 Japan 8.4.3 India 8.4.4 Rest of Asia Pacific 8.5 Rest of the World 8.5.1 Latin America 8.5.2 Middle East

9 Stem Cell Alopecia Treatment Market Competitive Landscape

9.1 Overview 9.2 Company Market Ranking 9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview 10.1.2 Financial Performance 10.1.3 Product Outlook 10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Customization of Report @ https://www.verifiedmarketresearch.com/product/stem-cell-alopecia-treatment-market/?utm_source=VN24&utm_medium=002

Highlights of Report

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne Fernandes Call: +1 (650) 781 4080 Email: [emailprotected]

Read more:
Stem Cell Alopecia Treatment Market Booming by Size, Revenue, Trend and Top Growing Companies 2026 - Vital News 24

Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine – India Education Diary

By Stell Cell Research

New Delhi: On Saturday, January 18th, 2020, the Advancells Group & the International Fertility Center together ended their first workshop Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020). The three-day workshop had specialized doctors, medical practitioners, learned scientists of Advancells, the leaders in cell manufacturing & processes and IFC, one of Indias most prestigious Fertility institute who were joined by candidates with MBBS/BAMS/BHMS/BPharma & Masters degree in Life Sciences.

The key-note speaker of the workshop was Dr. Rita Bakshi, founder and chairperson of International Fertility Centre, the oldest fertility clinic and one of the most renowned IVF clinics in India, one of the organizers of the event. Participants also had a privilege to listen to Dr. Sachin Kadam, CTO, Advancells and gain hands-on experience in the preparation of PRP; Liposuction method; and Bone Marrow aspiration. All these techniques were talked about at length and demonstrated in the form of manual & kit-based models to help the candidates gain exposure.

Dr. Punit Prabha, Head of Clinical Research and Dr. Shradha Singh Gautam, Head of Lab Operations at Advancells successfully set the base of stem cell biology for the participants who were experts in gynecology field, stem cell research and pain specialist. With the help of detailed analysis of Application of PRP for Skin rejuvenation; Preparation of Micro-fragmented Adipose Tissue and Nano Fat & SVF (Stromal Vascular Fraction) from Adipose Tissue; and Cell Culturing and Expansion in a Laboratory, applicants understood the application of stem cells in aesthetics, cosmetology, and anti-aging.

Vipul Jain, Founder & CEO of Advancells Group said, Educating young scientists about stem cells is important for us. With this workshop we wanted to discuss and share the challenges and lessons we have learned in our journey of curing our customers. We wanted to establish more concrete knowledge base in the presence of subject matter experts and help our attendees in more possible ways. We are hopeful to have successfully achieved what we claimed with this workshop.

Given the resounding success of the Sub-Specialty Training in Application of Regenerative Medicine (S.T.A.R. 2020), its hoped that the future events shall offer even greater wisdom to the participants by helping them improve and the lead the community into the age of greater awareness.

Advancells Group Advancells is leading the field of stem cell therapies in India and abroad, with representative offices in Bangladesh and Australia. The company provides arrangements for stem cell banking and protocols for partner doctors and hospitals which they can use for treating the patients using regenerative medicine. With a GMP compliant research and processing center that works on different cell lines from various sources such as Bone Marrow, Adipose Tissue, Dental Pulp, Blood, Cord Tissue etc. Advancells also intends to file a patent for this processing technology soon.

For more information, visit https://www.advancells.com/

International Fertility Centre IFC is Indias leading fertility center under the leadership and guidance of Dr. Rita Bakshi. She along with her solid team of experienced doctors have create a network of 10+ IVF clinics located in India and Nepal. Their services include In-vitro Fertilization (IVF), Intrauterine Insemination (IUI), Intracytoplasmic Injection (ICSI), Egg Donation, Surrogacy, Blastocyst, Assisted Hatching, Hysteroscopy, Laparoscopy and much more.

Read the rest here:
Advancells Group & IFC Concluded their 3-Day Workshop on Regenerative Medicine - India Education Diary

Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 – Fusion Science Academy

By Stell Cell Research

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Phase Change Materials (PCM) Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Phase Change Materials (PCM) market. We have also provided absolute dollar opportunity and other types of market analysis on the global Phase Change Materials (PCM) market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Phase Change Materials (PCM) market. All findings and data on the global Phase Change Materials (PCM) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Phase Change Materials (PCM) market available in different regions and countries.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2591133&source=atm

The authors of the report have segmented the global Phase Change Materials (PCM) market as per product, application, and region. Segments of the global Phase Change Materials (PCM) market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Phase Change Materials (PCM) market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Phase Change Materials (PCM) in these regions, from 2014 to 2025, coveringNorth America (United States, Canada and Mexico)Europe (Germany, UK, France, Italy, Russia and Turkey etc.)Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)South America (Brazil etc.)Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market includeBASFHoneywellCryopakEntropy SolutionsClimator SwedenPhase Change Energy SolutionsOutlast TechnologiesDow Building SolutionsChemours CompanyPCM EnergyRubitherm TechnologiesBy the product type, the market is primarily split intoOrganicInorganicBio-based

By the end users/application, this report covers the following segmentsBuilding & ConstructionRefrigerationConsumer GoodsOthers

We can also provide the customized separate regional or country-level reports, for the following regions:North AmericaUnited StatesCanadaMexicoAsia-PacificChinaJapanSouth KoreaIndiaAustraliaIndonesiaThailandMalaysiaPhilippinesVietnamEuropeGermanyFranceUKItalyRussiaCentral & South AmericaBrazilMiddle East & AfricaTurkeyGCC CountriesEgyptSouth Africa

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2591133&source=atm

Phase Change Materials (PCM) Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Phase Change Materials (PCM) Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Phase Change Materials (PCM) Market in South, America region is also expected to grow in near future.

The Phase Change Materials (PCM) Market report highlights is as follows:

This Phase Change Materials (PCM) market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Phase Change Materials (PCM) Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Phase Change Materials (PCM) Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Phase Change Materials (PCM) Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2591133&licType=S&source=atm

Read the original post:
Stem Cell Therapy Market : Segmentation, Industry Trends and Development to 2019-2026 - Fusion Science Academy

The Center for Breakthrough Medicines is Building the World’s Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)…

By Stem Cell Medical Center

KING OF PRUSSIA, Pa., Jan. 22, 2020 /PRNewswire/--The Discovery Labs and Deerfield Management Company have formed The Center for Breakthrough Medicines, a Contract Development and Manufacturing Organization (CDMO) and specialty investment company, to alleviate the critical lack of capacity that is preventing patients from accessing critically needed cell and gene therapies. The CDMO is occupying over 40 percent of The Discovery Labs' 1.6 million square foot biotech, healthcare and life sciences campus in King of Prussia, PA.

The CDMO provides preclinical through commercial manufacturing of cell and gene therapies and component raw materials. It offers process development, plasmid DNA,viral vectors, cell banking, cell processing, and support testing capabilities all under one roof. The immense $1.1 billion facility will provide instant capacity as the largest known single source for accelerating the delivery and affordability of lifesaving and life-changing therapies from the bench to the patient's bedside.

The Company has initiated a substantial hiring effort targeting the best and brightest of the life sciences community including, experts in CGMP manufacturing. The Company expects to hire over 2,000 team members within the next 30 months.

The CDMO has retained Nucleus Careers, a cloud-based specialty life sciences human capital recruiting and retention management expert, to buildout the entire team. Nucleus has proprietary recruiting and retention software designed for large scale human capital buildouts of high growth companies.

In addition to developing the world's largest single-point cell and gene therapy manufacturing facility, The Discovery Labs is establishing THE COLONY which will provide custom built discovery labs, breakthrough funding, sponsored research agreements, housing and relocation for the world's leading iconic experts in cell and gene therapy.

THE COLONY will seek to work hand in hand with scientists from both academic and pharmaceutical institutions to unlock and expedite groundbreaking therapies.

Marco A. Chacn, Ph.D., Founder of Paragon Bioservices and Chairman of The Discovery Labs states, "musicians, artists, members of religious communities and great thinkers throughout time have formed colonies where freedom of thought and expression combined with unlimited dreams and potential have resulted in the world's greatest accomplishments." Dr. Chacn went on to say, "the goal of THE COLONY is to unshackle the potential of the world's greatest scientific minds."

The ability for the industry's greatest scientists to cohabitate, collaborate, cooperate, and communicate via technology and in person will create an exponential therapeutic "X FACTOR." THE COLONY seeks to unlock institutional barriers prohibiting the world's greatest scientists from moving at a pace necessary in today's ever-changing therapeutic revolution. THE COLONY will partner with the institutions where the scientists currently work by providing equity, license fees, and revenue sharing.

"The Center for Breakthrough Medicines will be serving companies from the earliest stages through commercialization. Its exceptional scale and offering will quickly relieve the production bottleneck for advanced therapies by reducing the time, complexity, and cost of commercializing vitally needed gene and cell therapies," noted Audrey Greenberg, Board Member and Executive Managing Director for The Discovery Labs.

The addition of this end-to-end manufacturing capability is expected to significantly enhance the offerings of The Discovery Labs in an area that has become one of the largest life sciences hubs in the world. Renovations are underway to construct a total of 86 plasmid, viral vector production, universal cell processing, CGMP testing, process development and cell banking suites. The viral vector and cell processing suites will be fully compliant with both U.S. Food and Drug Administration and European Medicines Agency standards. All suites will offer the flexibility to meet client-specific workflows and will be able to adapt quickly to meet demand. The Company is in the process of reserving capacity now for late 2020.

"Today brilliant scientists are advancing an unprecedented number of gene and cell therapy drug candidates. The real tragedy, however, is a scarcity of manufacturing know-how, which is complex and expensive," said Alex Karnal, Partner and Managing Director of Deerfield Management and a Board Member of the Discovery Labs. "With its visionary business model, it is hoped that The Center for Breakthrough Medicines will help realize the promise of cell and gene therapies in time to treat the many patients who need them."

The Discovery Labs provides a central campus where the world's greatest scientists can collaborate on new therapeutic discoveries to eradicate diseases affecting small and large segments of the global population. The Center for Breakthrough Medicines will work with these leaders, life sciences companies, large pharmaceutical companies, and academic and government institutions.

This new manufacturing capability is a transformational addition to The Discovery Labs market offering and dovetails with The Discovery Labs biotech incubator, Unite IQ. Unite IQ offers immediate space to emerging life sciences companies and scientists giving them the ability to grow from startup to enterprise company on one campus. The incubator and accelerator space at Unite IQ provides a comprehensive home for startups with every resource needed to initiate business operations. Unite IQ tenants are expected to utilize the discovery, development, testing, and manufacturing capabilities of the Center for Breakthrough Medicines with seamless forward integration of processes and analytics, and seamless tech transfer from research lab to large scale production

The Emerging Field of Cell and Gene Therapy in Pennsylvania

The demand for clinical and commercial manufacturing capacity is acute and expected to remain that way. The current shortfall in manufacturing for cell and gene therapies is severely underserved with few approved products. There are currently approximately 1,100 advanced therapies in the pipeline pending FDA approval. This will greatly increase highly skilled manufacturing demand. Dr. Peter Marks, Director of the FDA Center for Biologics Evaluation and Research, states, "what keeps me up at night is will we be able to manufacture these on a scale that will allow us to bring the benefit of these therapies to patients?"He further added that "if we can help see cost of goods and ability to manufacture reproducibly improve, I think that'll be a big thing."All of this adds up to a supply constrained market that The Center for Breakthrough Medicines aims to help address.

With the potential to treat and even cure disabling, and deadly diseases, gene and cell therapies are ushering in a new era of medicine. These therapies may eventually be able to cure genetic conditions, such as cystic fibrosis, hemophilia A, and a range of cancers. The Philadelphia area has become the epicenter for the flourishing field of gene and cell therapy. Research from CBRE currently ranks the market among the top biotech clusters for medical research and health services. The cluster has become known worldwide as "Cellicon Valley"for its leadership in research and development of this rapidly evolving field. The Discovery Lab's suburban Philadelphia location offers a talent rich environment due to the area's preponderance of large pharmaceutical companies and the Philadelphia region's position boasting the top 10 universities and primary school systems in nation.

Over the past three years, multiple Philadelphia companies have received approvals for major breakthroughs in cell and gene therapy. In 2017, the U.S. FDA approved the first-ever CAR-T cell therapy, Novartis's Kymriah, which originated at the University of Pennsylvania. Shortly thereafter, the FDA gave landmark approval for the first-ever gene therapy to treat a genetic blindness condition to Spark Therapeutics, a start-up founded by researchers at Children's Hospital of Philadelphia. These discoveries and others in the pipeline are attracting billions of dollars of venture capital. The Greater Philadelphia Region set a recent record in venture capital financing.

The Discovery Labs Center for Breakthrough Medicines joins more than 25 healthcare, life sciences and tech-enabled companies that already call The Discovery Labs King of Prussia home.

Brian O'Neill, Founder of The Discovery Labs Center for Breakthrough Medicines, and Tony Khoury, Board Member of The Discovery Labs and Engineer at Project Pharma, will be speaking at the 2020 PhacilitateWorld Stem Cell Summit discussing The Future of Gene Therapy Manufacturing at 4 p.m. today at the Hyatt Regency in Miami, Florida.

Contact Audrey Greenberg at agreenberg@thediscoverylabs.com for more information about development services, manufacturing capacity, incubator space or leasing information at the property.

About The Discovery LabsPart of MLP Ventures, The Discovery Labs is a global provider of world-class cGMP manufacturing, turnkey laboratory solutions, critical materials and office space that support therapeutic products and services to the biotechnology and pharmaceutical industry so that groundbreaking medicines get to the patients that need them. The location in eastern King of Prussia is a prototype for a global rollout of The Discovery Labs, providing Big Pharma, emerging life sciences, consumer and technology companies flexible, end-to-end technical real estate and business infrastructure for the customer's entire lifecycle from discovery to delivery, including manufacturing capacity. It is the first fully integrated environment that merges technology and life sciences under one roof to drive innovation.

About Deerfield Management

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.

Media Contact:Tony DeFazio, DeFazio Communications(o) 484-534-3306 (c) 484-410-1354tony@defaziocommunications.com

SOURCE The Discovery Labs

The Discovery Labs

The rest is here:
The Center for Breakthrough Medicines is Building the World's Largest Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO)...

Toxys Strengthens Leadership Team with Appointment of CBO and COO Positions – BioSpace

By Stem Cell Medical Center

LEIDEN, The Netherlands, January 21, 2020 /B3C newswire/ --Today,Toxysannounces the appointment of a Chief Business Officer (CBO) and a Chief Operating Officer (COO). Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative, high-fidelityin vitrotoxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industries. With this strengthened leadership, Toxys will further accelerate business growth to become an industry-leader in animal-free chemical safety testing.

Paula van Rossumis promoted toCBO. Paula joined Toxys in 2016 as Director Business Development & Sales and has been instrumental for the business growth of Toxys. Paula holds a MSc degree from Leiden University in Biomedical Sciences and Science-based Business.

Remco Derris promoted toCOO. Remco joined Toxys in 2014 as lab manager and product specialist. He has been instrumental for management of all commercial toxicity screening as well operational management of the R&D laboratory. Remco holds a MSc degree from Leiden University in Biomedical Sciences.

Paula and Remco are valuable additions to the senior Toxys Management Team. Their proven experience and expertise in business development, sales, customer relations and lab management will further boost the growth of Toxyssaid Giel Hendriks, CEO of Toxys BV.

Link to the press release

Tweet this press release

AboutToxysToxys is a Dutch biotech companythat offers a broad spectrum of innovativein vitrotoxicology solutions. Toxys was founded in 2014 as a spin-off from the Leiden University Medical Center and has its state-of-the-art laboratory facilities located at the Leiden BioScience Park. We are experts in the field of genetic and developmental toxicology with a focus on Mode-of-Action. We are dedicated to bringing relevant information to our clients on potential human health hazards of novel and existing drugs, chemicals and other substances. Toxys is currently working with 7 of the Top10 global Pharma companies and several major chemical, cosmetics and food multinationals.

Toxys has developed the unique ToxTracker and ReproTracker assays. ToxTracker is a high-throughput stem cell-based reporter suite of assays that allows reliable identification of genotoxic carcinogens. ToxTracker provides mechanistic insight into undesired properties of chemicals. ReproTracker is currently under development and its commercial launch (planned for early 2020) will allowin vitrodevelopmental toxicity hazard identification. These assays can be particularly useful in Mode-of-Action and Adverse Outcome Pathway (AOP) approaches for chemical safety assessment.

We offer ToxTracker and ReproTracker as tailored service to our customers, often in combination with standard toxicology assays or under license and as kits for use in partners own laboratories. Toxys is highly valued for its scientific expertise, high quality results and responsiveness.

Contact

Giel HendriksCEO+31 71 3322474g.hendriks@toxys.com

Media Contact

Paula van RossumCBO+31 71 3322470p.vanrossum@toxys.com

Keywords: Humans; Carcinogens; Chemical Safety; Cosmetics; Carcinogenesis; Industry; Food Industry; DNA Damage; Drug-Related Side Effects and Adverse Reactions; Mutagenicity Tests; Biotechnology

The rest is here:
Toxys Strengthens Leadership Team with Appointment of CBO and COO Positions - BioSpace

Share the Love on Valentine’s Day! Join the Cure 4 The Kids Foundation Blood Drive and Registry Event – Nevada Business Magazine

By Stem Cell Medical Center

LAS VEGAS Regardless of your relationship status on Valentines Day, you can have an incredible impact on someones life in our communityand possibly save a life by donating blood or by becoming part of the bone marrow registry.

Cure 4 The Kids Foundation is well aware of the national shortage of blood and platelets, and how vital a reliable blood supply is to the on-going health of our community. Thats why Cure 4 The Kids Foundation is organizing the Valentines Day Blood Drive and Bone Marrow Registry Event on Friday, February 14, 2020.

The public is strongly encouraged to take part in either effort between 9:00 a.m. and 4:00 p.m. at One Breakthrough Way, Las Vegas, Nevada 89135.

Blood donors can ensure an easy and relatively quick donation process by making an appointment prior to Valentines Day by going towww.bloodhero.comand entering the code: cure4kids under sponsor. You can also schedule an appointment by calling Vitalant at 877-25-VITAL. The Vitalant bloodmobile will be parked in front of the One Breakthrough Way building.

Blood Donation Reminders:

Blood donors must be at least 16 years old (16 and 17-year olds must bring a signed permission form from a parent or guardian)Weigh at least 110 poundsBe in good general healthDrink plenty of water 24 to 48 hours prior to donationBring ID

Cure 4 The Kids Foundation is also partnering with the Be The Match Registry. The registry offers hope to those affected by cancer and other conditions by matching potential blood stem cell donors with those who are in need of a transplant.

The first step in joining the registry is to undergo a mouth swab by one of our volunteers. Those who are a possible match will be contacted at a later time. This service is free and available between 9:00 a.m. and 4:00 p.m. on February 14, 2020, in the lobby of the One Breakthrough Way building.

Bone Marrow Registry Reminders:

Donors between 18 and 44 years of age are especially neededYou cannot become a donor if you had have certain diseasesLearn more atjoin.bethematch.org

About Cure 4 The Kids Foundation

Founded in Las Vegas in 2007, Cure 4 The Kids Foundation exists to provide high-quality, research-focused medical treatment to children battling cancer and many other life-threatening conditions. Cure 4 The Kids Foundation operates the only outpatient childhood cancer treatment center in the State of Nevada and is proudly accredited by The Joint Commission. This stringent medical accreditation and the required unannounced inspections ensure that patients are getting the best care possible. From the beginning, the mission of Cure 4 The Kids Foundation has been to bring increased community access to these specialized treatments that are leading the way to improved patient outcomes. Cure 4 The Kids Foundations Charity Care Program provides high-quality treatment to those who are uninsured, underinsured and those unable to pay for treatment. No patient is ever turned away for financial reasons. We are a 501(c)(3) nonprofit organization.www.cure4thekids.org

Continued here:
Share the Love on Valentine's Day! Join the Cure 4 The Kids Foundation Blood Drive and Registry Event - Nevada Business Magazine

Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit – Yahoo Finance

By Stem Cell Medicine

CEO Sandy Solmon to Present on Celavies Stem Cell Therapies at Upcoming Conferences in New York and Barcelona

Celavie Biosciences, LLC, a company working to improve lives and restore hope by advancing innovations in CNS diseases with regenerative stem cell-based therapies, today announced their presentation of a poster, titled "Five year follow-up on the first-in-human transplantation of undifferentiated stem cells into Parkinsonian patients reveals no adverse effects with improvement in motor function or arrest of the disease progression in five out of seven patients," at the Phacilitate Leaders World and World Stem Cell Summit, held January 21-24 in Miami, Florida.

The poster shows five-year follow-up data that expands on the exploratory clinical data in 7 PD patients with four-year follow-up published in Cell Transplantation in 2018. Oleg Kopyov, Executive Vice President and Chief Scientific Officer at Celavie, presented the poster on-site at the Miami Hyatt Regency.

In the results at one year after cell grafting, all but two of the seven patients completing the study showed various degrees of motor improvement, and five of them showed better response to medication. At five-year evaluation, Unified Parkinsons Disease Rating Scale III (UPDRS III) scores remained better than at baseline in 4/7 patients in the OFF condition and in 5/7 patients in the ON condition. None of the patients showed unwanted motor disturbances (dyskinesias), tumor formation, or any detectable immune responses to the grafted cells.

"We are excited that the five-year data for our exploratory clinical trial suggest that the neural progenitor cells are able to stop or slow down the motor deterioration in Parkinsons patients that one would expect to see in this timespan, showing continued improvement even compared to the fourth year," said Oleg Kopyov. "We anticipate filing an IND with the FDA for a Phase I U.S. trial in patients with moderate to advanced Parkinsons disease this year."

In addition, Sandy Solmon, Celavies CEO, will deliver presentations at two upcoming international industry conferences:

Ms. Solmon will discuss Celavies application of the companys human undifferentiated allogeneic pluripotent stem cells in Parkinsons disease, as well as pre-clinical data in cerebellar ataxia and upcoming milestones. To schedule a meeting with Celavie Biosciences at these conferences, please contact: Mary Beth Cicero at mbcicero@lavoiehealthscience.com.

About the World Stem Cell Summit

Produced by the non-profit Regenerative Medicine Foundation (RMF), and in its 15th year, the World Stem Cell Summit will take place January 21-24, 2020, in Miami, Florida in partnership with Phacilitate Leaders World, as part of Advanced Therapies Week. The Summit is the most inclusive and expansive interdisciplinary, networking, and partnering meeting in the stem cell science and regenerative medicine field. With the overarching purpose of fostering translation of biomedical research, funding, and investments targeting cures, the Summit and co-located conferences serve a diverse ecosystem of stakeholders. For more information about the upcoming World Stem Cell Summit in Miami, please visit: http://www.worldstemcellsummit.com.

About Celavie Biosciences

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope by advancing regenerative stem cell therapies for the treatment of Parkinsons disease and other disorders of the central nervous system (CNS). The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases. More information is available at https://www.celavie.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005497/en/

Contacts

Hannah MongeonLaVoieHealthScience(617)655-6765hmongeon@lavoiehealthscience.com

Read the original post:
Celavie Biosciences Presented Five-Year Follow-Up Data in Parkinsonian Patients at the World Stem Cell Summit - Yahoo Finance

The Brave New World of Organoids – North Forty News

By Stem Cell Medicine

PHOTO COURTESY OF ROANE STATE COMMUNITY COLLEGE, TN: Typical nervous tissue that can now be grown as organoids in the lab.

Bio Bites

By R. Gary Raham

One of the big scientific news stories of 2019 involved the use of organoids to help fight disease, and to learn more about how embryos build entire human beings from one fertilized egg cell. The term organoids has a science fictiony sound to it. A title like Attack of the organoids wouldnt be out of place in an SF library. Actually, the ability to create specialized tissuelike bundles of brain neurons that hook together to transmit nerve impulsescan raise a few hairs on ones neck. But organoids do hold great promise for curing diseases, broadening our understanding of development, and personalizing medical treatments.

Stem cells allow scientists to build organoids. Stem cells are like major subcontractors produced by embryos to build the various organs and organ systems we depend on. These pluripotent cells (cells that can differentiate in many ways) can produce brain, kidney, lung, intestinal, stomach, and liver tissue. The tissue clumps produced tend to be smallroughly the size of a peapartly because they dont have access to the circulatory system the body uses to provide oxygen and nutrients and remove wastes. Scientists have to provide work-arounds to keep organoids alive and functioning.

One of the amazing things about organoids is that they self-organize into recognizable tissues without input from an entire body. Take brain cells for example. The neurons produced by stem cells link up and form networks that are capable of transmitting nerve impulses like an intact, complete brain. One leading researcher in this field of study is Alysson Muotri, a biologist at University of California San Diego School of Medicine. His website is http://www.medschool.ucsd.edu. He also has a fascinating series of YouTube videos called Building The Brain With Alysson Muotri. Muotri was senior author on a paper in 2019 in Cell Stem Cell. His lab was able to nurture the growth of brain organoids for many months. After four months electrical activity in the organoids began to increase exponentially. By twenty-five weeks, a computer program had a hard time distinguishing between brain wave patterns produced by organoids and pre-term babies.

Brain tissue organoids also hold promise for studying conditions like autism in human beingsa kind of neurological condition marked by differences in learning styles, repetitive motions, and sometimes difficulty with language and communication. The Harvard Stem Cell Institute is also studying how the Zika virus associates with microcephaly (small brain syndrome) during early embryo development.

Someday, scientists may be able to routinely take stem cells from individuals and test the efficacy of drugs on that persons liver cells, for example, to make sure those drugs wont produce harmful or fatal effects.

The brave new world of organoids is comingand not just in the next SF novel you read.

Go here to read the rest:
The Brave New World of Organoids - North Forty News

The Tiny Brain Cells That Connect Our Mental and Physical Health – WIRED

By Stem Cell Medicine

When enlarged under a high-resolution microscope, microglia resemble elegant tree branches with many slender limbs. As they pass by neurons, microglia extend and retract their tiny arm-like protrusions, tapping on each neuron as if to inquire, Are we good here? All okay? Or not okay?as a doctor might palpate a patients abdomen, or check reflexes by tapping on knees and elbows.

Back in 2004, Barres and Stevens were examining how synapses originally come to be pruned to form a healthy brain during early, normal development. Theyd recently discovered that immune molecules known as complement were sending out eat me signals from some brain synapses, and these synapsestagged with a kind of kiss of death signagewere destroyed. Think of the way you click and tag emails that you want deleted from your inbox. Your email servers software recognizes those tags, and when you click on the Trash icon, bing, theyre gone. Thats similar to what Stevens and Barres were seeing happen to brain synapses that were tagged by complement. They disappeared.

What they described happening in the brain, which they reported in the journal Cell in 2007, echoed a similar process that was well-understood to happen in the body. When a cell dies in a bodily organ, or if the bodys immune system senses a threatening pathogen, complement molecules tag those unwanted cells and invaders for removal. Then, a type of white blood cell known as macrophagesGreek for big eatersrecognizes the tag, engulfs the cell or pathogen, and destroys it. In the body, macrophages play a role in inflammation as well as in autoimmune diseases like rheumatoid arthritis and Guillain Barre. When activated, they can mistakenly go too far in their effort to engulf and destroy pathogens and spew forth a slew of inflammatory chemicals that begin to do harm to the bodys own tissue.

Stevens and Barres werent sure what was eating away at these tagged synapses, causing them to disappear in the brain, but Stevens had a hunch that it might have something to do with microglia.

We could see that when microglia sensed even the smallest damage or change to a neuron, they headed, spider-like, in that neurons direction, then they drew in their limbs and morphed into small, amoeba-like blobs, Stevens says. Soon after, those same synapses disappeared. Poof.

Could microglia be the culprit at the center of it all, the macrophage corollary in the brain, responding to eat me signals and pruning the brains circuitry during development? And what if this process was not only taking place in utero? Stevens wondered, when she first saw microglia behaving this way. What if it was also being mistakenly turned back on again later in life, during the teen years, or in adulthoodonly now its a bad thing and microglia are sometimes mistakenly engulfing and destroying healthy brain synapses too?

You can imagine how you could have too many synapses, or not enough synapse connectivity, Stevens says, her hands spreading wide with excitement. And you can imagine, given how our brain works, if that connectivity is even slightly off, that could potentially underlie a range of neuropsychiatric and cognitive disorders.

When she landed at Harvard, Stevens and her postdoc, Dori Schafer, tried to get a closer look at what microglia were up to in the brain. Schafer injected dye into the eyes of mice, which she then traced down from the neurons in the eye nerves and into the brain. This made the brains synapses glow bright fluorescent red. Microglia were stained fluorescent green. If they saw structuresthe synapsesglowing like red, fluorescent lit-up dots inside the bellies of the green microglia, they would know that microglia were eating synapses.

Six months into their efforts, Schafer came running into Stevenss office with photo images flapping in her hand. Theyre in there! she told Stevens. The synapses are inside the microglia! We can see it! It was such a high-five moment, Stevens recalls. Microglia were like tiny little Pac-Men in the brainand brain synapses were in the belly of the Pac-Men! We felt we were on to something really wonderful, really novel. This was deeply important in terms of looking ahead to microglias role in disease.

Read the original:
The Tiny Brain Cells That Connect Our Mental and Physical Health - WIRED

→←